Pfizer, Merck Beat Q2 Views; Sanofi Makes PD-1 Deal

By | July 28, 2015

Scalper1 News

Big pharmas Pfizer (PFE) and Merck (MRK) both beat Q2 estimates and raised guidance Tuesday, while Merck and French counterpart Sanofi (SNY) entered into separate deals to develop immunotherapy drugs for cancer. Pfizer’s earnings dipped 3% to 56 cents a share, but topped analysts’ consensus by 4 cents, according to Thomson Reuters. Sales declined 7% to $11.85 billion, more than $400 million ahead of the Street’s number. Pfizer now sees full-year Scalper1 News

Scalper1 News